Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy
Purpose: To report the visual and anatomical outcomes of intravitreal ziv-aflibercept (IVZ) and bevacizumab (BVZ) monotherapy in treatment-naive polypoidal choroidal vasculopathy (PCV). Methods: This was a retrospective case series of 16 eyes (8 eyes each in IVZ and BVZ groups). The study period was...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2019-01-01
|
| Series: | Indian Journal of Ophthalmology |
| Subjects: | |
| Online Access: | http://www.ijo.in/article.asp?issn=0301-4738;year=2019;volume=67;issue=7;spage=1114;epage=1118;aulast=Singh |
| _version_ | 1818367347564478464 |
|---|---|
| author | Sumit Randhir Singh Niroj Kumar Sahoo Nallamasa Rohit Goud Jay Chhablani |
| author_facet | Sumit Randhir Singh Niroj Kumar Sahoo Nallamasa Rohit Goud Jay Chhablani |
| author_sort | Sumit Randhir Singh |
| collection | DOAJ |
| description | Purpose: To report the visual and anatomical outcomes of intravitreal ziv-aflibercept (IVZ) and bevacizumab (BVZ) monotherapy in treatment-naive polypoidal choroidal vasculopathy (PCV). Methods: This was a retrospective case series of 16 eyes (8 eyes each in IVZ and BVZ groups). The study period was from January 2016 to March 2018. The inclusion criteria were treatment-naive PCV patients who were treated with either IVZ or BVZ monotherapy on pro re nata protocol and followed up monthly for 6 months. The change in best-corrected visual acuity (BCVA), central macular thickness (CMT), and pigment epithelial detachment (PED) height was measured at baseline and 6 months. Results: A total of 16 eyes were studied. IVZ group had an improvement in BCVA by 0.15 logarithm of minimum angle of resolution (logMAR; approximately 1.5 lines) at 6 months, whereas BVZ group had a reduction in BCVA by 0.21 logMAR (approximately 2 lines) (P = 0.027). Five patients and one patient in IVZ and BVZ groups, respectively, had ≥5 letters gain of BCVA. IVZ group had significant reduction in PED height (P = 0.048), whereas the change in CMT was not significant at 6 months (P = 0.681). The mean number of injections (2.87 ± 0.83 in IVZ and 2.25 ± 0.89 BVZ group; P = 0.168) and longest treatment-free interval (3.00 ± 2.20 months in IVZ and 2.12 ± 1.96 months in BVZ group; P = 0.41) were not significantly different. Conclusion: The visual and anatomical outcomes in terms of PED reduction in treatment-naive PCV patients were better in IVZ group compared with BVZ. IVZ monotherapy is a viable, cost-effective alternative in these patients with good safety profile. |
| first_indexed | 2024-12-13T22:50:37Z |
| format | Article |
| id | doaj.art-e1cbb80982c747ae89c4c2f70ec01983 |
| institution | Directory Open Access Journal |
| issn | 0301-4738 1998-3689 |
| language | English |
| last_indexed | 2024-12-13T22:50:37Z |
| publishDate | 2019-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Indian Journal of Ophthalmology |
| spelling | doaj.art-e1cbb80982c747ae89c4c2f70ec019832022-12-21T23:28:38ZengWolters Kluwer Medknow PublicationsIndian Journal of Ophthalmology0301-47381998-36892019-01-016771114111810.4103/ijo.IJO_638_18Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathySumit Randhir SinghNiroj Kumar SahooNallamasa Rohit GoudJay ChhablaniPurpose: To report the visual and anatomical outcomes of intravitreal ziv-aflibercept (IVZ) and bevacizumab (BVZ) monotherapy in treatment-naive polypoidal choroidal vasculopathy (PCV). Methods: This was a retrospective case series of 16 eyes (8 eyes each in IVZ and BVZ groups). The study period was from January 2016 to March 2018. The inclusion criteria were treatment-naive PCV patients who were treated with either IVZ or BVZ monotherapy on pro re nata protocol and followed up monthly for 6 months. The change in best-corrected visual acuity (BCVA), central macular thickness (CMT), and pigment epithelial detachment (PED) height was measured at baseline and 6 months. Results: A total of 16 eyes were studied. IVZ group had an improvement in BCVA by 0.15 logarithm of minimum angle of resolution (logMAR; approximately 1.5 lines) at 6 months, whereas BVZ group had a reduction in BCVA by 0.21 logMAR (approximately 2 lines) (P = 0.027). Five patients and one patient in IVZ and BVZ groups, respectively, had ≥5 letters gain of BCVA. IVZ group had significant reduction in PED height (P = 0.048), whereas the change in CMT was not significant at 6 months (P = 0.681). The mean number of injections (2.87 ± 0.83 in IVZ and 2.25 ± 0.89 BVZ group; P = 0.168) and longest treatment-free interval (3.00 ± 2.20 months in IVZ and 2.12 ± 1.96 months in BVZ group; P = 0.41) were not significantly different. Conclusion: The visual and anatomical outcomes in terms of PED reduction in treatment-naive PCV patients were better in IVZ group compared with BVZ. IVZ monotherapy is a viable, cost-effective alternative in these patients with good safety profile.http://www.ijo.in/article.asp?issn=0301-4738;year=2019;volume=67;issue=7;spage=1114;epage=1118;aulast=SinghIntravitreal bevacizumabintravitreal ziv-afliberceptpolypoidal choroidal vasculopathy |
| spellingShingle | Sumit Randhir Singh Niroj Kumar Sahoo Nallamasa Rohit Goud Jay Chhablani Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy Indian Journal of Ophthalmology Intravitreal bevacizumab intravitreal ziv-aflibercept polypoidal choroidal vasculopathy |
| title | Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy |
| title_full | Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy |
| title_fullStr | Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy |
| title_full_unstemmed | Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy |
| title_short | Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy |
| title_sort | comparison of intravitreal ziv aflibercept and bevacizumab monotherapy in treatment naive polypoidal choroidal vasculopathy |
| topic | Intravitreal bevacizumab intravitreal ziv-aflibercept polypoidal choroidal vasculopathy |
| url | http://www.ijo.in/article.asp?issn=0301-4738;year=2019;volume=67;issue=7;spage=1114;epage=1118;aulast=Singh |
| work_keys_str_mv | AT sumitrandhirsingh comparisonofintravitrealzivafliberceptandbevacizumabmonotherapyintreatmentnaivepolypoidalchoroidalvasculopathy AT nirojkumarsahoo comparisonofintravitrealzivafliberceptandbevacizumabmonotherapyintreatmentnaivepolypoidalchoroidalvasculopathy AT nallamasarohitgoud comparisonofintravitrealzivafliberceptandbevacizumabmonotherapyintreatmentnaivepolypoidalchoroidalvasculopathy AT jaychhablani comparisonofintravitrealzivafliberceptandbevacizumabmonotherapyintreatmentnaivepolypoidalchoroidalvasculopathy |